Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc. DRUG.CN Peers
See (DRUG.CN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DRUG.CN | CA$35.25 | -7.33% | 249.7M | -185.53 | -CA$0.19 | N/A |
| BLU.TO | CA$19.48 | -0.10% | 2.5B | -20.29 | -CA$0.96 | N/A |
| MMED.NE | CA$14.90 | +9.48% | 1.1B | -4.50 | -CA$3.31 | N/A |
| FRX.TO | CA$11.25 | N/A | 310.7M | -15.41 | -CA$0.73 | N/A |
| CYBN.NE | CA$10.91 | -1.27% | 229.4M | -2.20 | -CA$4.96 | N/A |
| EPRX.TO | CA$5.34 | -1.29% | 191.4M | -5.13 | -CA$1.04 | N/A |
| MSCL.TO | CA$0.65 | +1.54% | 114.4M | 2.71 | CA$0.24 | N/A |
| GLAB.CN | CA$1.02 | +10.91% | 76.4M | -20.40 | -CA$0.05 | N/A |
| MSET.CN | CA$0.74 | -1.33% | 75M | -12.33 | -CA$0.06 | N/A |
| MDNA.TO | CA$0.95 | -6.86% | 74.3M | -2.64 | -CA$0.36 | N/A |
Stock Comparison
DRUG.CN vs BLU.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while BLU.TO trades at CA$19.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, DRUG.CN is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MMED.NE Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MMED.NE has a market cap of 1.1B. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MMED.NE trades at CA$14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MMED.NE's P/E ratio is -4.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MMED.NE's ROE of -0.33%. Regarding short-term risk, DRUG.CN is less volatile compared to MMED.NE. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs FRX.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, FRX.TO has a market cap of 310.7M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while FRX.TO trades at CA$11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas FRX.TO's P/E ratio is -15.41. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to FRX.TO's ROE of +0.19%. Regarding short-term risk, DRUG.CN is more volatile compared to FRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs CYBN.NE Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, CYBN.NE has a market cap of 229.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while CYBN.NE trades at CA$10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas CYBN.NE's P/E ratio is -2.20. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CYBN.NE's ROE of -0.39%. Regarding short-term risk, DRUG.CN is more volatile compared to CYBN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs EPRX.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, EPRX.TO has a market cap of 191.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while EPRX.TO trades at CA$5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas EPRX.TO's P/E ratio is -5.13. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to EPRX.TO's ROE of -1.21%. Regarding short-term risk, DRUG.CN is more volatile compared to EPRX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MSCL.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MSCL.TO has a market cap of 114.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MSCL.TO trades at CA$0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MSCL.TO's P/E ratio is 2.71. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MSCL.TO's ROE of -0.74%. Regarding short-term risk, DRUG.CN is less volatile compared to MSCL.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs GLAB.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, GLAB.CN has a market cap of 76.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while GLAB.CN trades at CA$1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas GLAB.CN's P/E ratio is -20.40. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to GLAB.CN's ROE of +1.38%. Regarding short-term risk, DRUG.CN is more volatile compared to GLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MSET.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MSET.CN has a market cap of 75M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MSET.CN trades at CA$0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MSET.CN's P/E ratio is -12.33. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MSET.CN's ROE of -3.17%. Regarding short-term risk, Volatility data is not available for a full comparison. DRUG.CN has daily volatility of 2.49 and MSET.CN has daily volatility of N/A.
DRUG.CN vs MDNA.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MDNA.TO has a market cap of 74.3M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MDNA.TO trades at CA$0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MDNA.TO's P/E ratio is -2.64. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MDNA.TO's ROE of -1.64%. Regarding short-term risk, DRUG.CN is less volatile compared to MDNA.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs HBP.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, HBP.TO has a market cap of 68.2M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while HBP.TO trades at CA$0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas HBP.TO's P/E ratio is -0.88. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to HBP.TO's ROE of +21.43%. Regarding short-term risk, DRUG.CN is more volatile compared to HBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs ONCO.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, ONCO.CN has a market cap of 63.8M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while ONCO.CN trades at CA$1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas ONCO.CN's P/E ratio is -147.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ONCO.CN's ROE of -3.52%. Regarding short-term risk, DRUG.CN is more volatile compared to ONCO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs SVA.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, SVA.TO has a market cap of 57.5M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while SVA.TO trades at CA$0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas SVA.TO's P/E ratio is -1.94. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to SVA.TO's ROE of +2.30%. Regarding short-term risk, DRUG.CN is less volatile compared to SVA.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs PMN.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, PMN.TO has a market cap of 51.5M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while PMN.TO trades at CA$6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas PMN.TO's P/E ratio is -1.78. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to PMN.TO's ROE of -5.57%. Regarding short-term risk, DRUG.CN is less volatile compared to PMN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MBX.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MBX.TO has a market cap of 47.9M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MBX.TO trades at CA$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MBX.TO's P/E ratio is 34.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MBX.TO's ROE of +0.07%. Regarding short-term risk, DRUG.CN is more volatile compared to MBX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs DTC.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, DTC.CN has a market cap of 42.1M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while DTC.CN trades at CA$0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas DTC.CN's P/E ratio is -9.62. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to DTC.CN's ROE of +1.22%. Regarding short-term risk, DRUG.CN is less volatile compared to DTC.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs IGX.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, IGX.TO has a market cap of 41.9M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while IGX.TO trades at CA$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas IGX.TO's P/E ratio is -3.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IGX.TO's ROE of +0.39%. Regarding short-term risk, DRUG.CN is less volatile compared to IGX.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs ONC.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, ONC.TO has a market cap of 41.7M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while ONC.TO trades at CA$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas ONC.TO's P/E ratio is -1.17. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ONC.TO's ROE of -2.25%. Regarding short-term risk, DRUG.CN is less volatile compared to ONC.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs PREV.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, PREV.CN has a market cap of 38.2M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while PREV.CN trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas PREV.CN's P/E ratio is -45.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to PREV.CN's ROE of +0.19%. Regarding short-term risk, DRUG.CN is more volatile compared to PREV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs DOSE.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, DOSE.CN has a market cap of 27M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while DOSE.CN trades at CA$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas DOSE.CN's P/E ratio is -5.25. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to DOSE.CN's ROE of +1.61%. Regarding short-term risk, DRUG.CN is less volatile compared to DOSE.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs BCT.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, BCT.TO has a market cap of 26.5M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while BCT.TO trades at CA$4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas BCT.TO's P/E ratio is -0.69. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BCT.TO's ROE of +66.06%. Regarding short-term risk, DRUG.CN is less volatile compared to BCT.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs AEZS.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, AEZS.TO has a market cap of 25.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while AEZS.TO trades at CA$8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas AEZS.TO's P/E ratio is -2.61. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to AEZS.TO's ROE of -0.67%. Regarding short-term risk, DRUG.CN is less volatile compared to AEZS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs PHRM.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, PHRM.CN has a market cap of 18.6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while PHRM.CN trades at CA$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas PHRM.CN's P/E ratio is -4.20. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to PHRM.CN's ROE of -0.83%. Regarding short-term risk, DRUG.CN is more volatile compared to PHRM.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs REUN.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, REUN.TO has a market cap of 16.6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while REUN.TO trades at CA$1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas REUN.TO's P/E ratio is -0.43. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to REUN.TO's ROE of -1.10%. Regarding short-term risk, DRUG.CN is more volatile compared to REUN.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs TELI.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, TELI.CN has a market cap of 15.8M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while TELI.CN trades at CA$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas TELI.CN's P/E ratio is -9.83. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TELI.CN's ROE of -2.08%. Regarding short-term risk, DRUG.CN is more volatile compared to TELI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs IMV.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, IMV.TO has a market cap of 13.1M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while IMV.TO trades at CA$1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas IMV.TO's P/E ratio is -0.18. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IMV.TO's ROE of -4.95%. Regarding short-term risk, DRUG.CN is less volatile compared to IMV.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs RVX.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, RVX.TO has a market cap of 12.8M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while RVX.TO trades at CA$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas RVX.TO's P/E ratio is -4.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to RVX.TO's ROE of +0.06%. Regarding short-term risk, DRUG.CN is more volatile compared to RVX.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs BETR.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, BETR.CN has a market cap of 12.3M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while BETR.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas BETR.CN's P/E ratio is -3.17. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BETR.CN's ROE of +0.43%. Regarding short-term risk, DRUG.CN is less volatile compared to BETR.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs GLOW.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, GLOW.CN has a market cap of 12.2M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while GLOW.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas GLOW.CN's P/E ratio is -2.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to GLOW.CN's ROE of +12.80%. Regarding short-term risk, DRUG.CN is more volatile compared to GLOW.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs TBP.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, TBP.TO has a market cap of 10.6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while TBP.TO trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas TBP.TO's P/E ratio is -0.31. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TBP.TO's ROE of -4.68%. Regarding short-term risk, DRUG.CN is more volatile compared to TBP.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MDMA.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MDMA.CN has a market cap of 10M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MDMA.CN trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MDMA.CN's P/E ratio is -4.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MDMA.CN's ROE of -0.86%. Regarding short-term risk, DRUG.CN is less volatile compared to MDMA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs BLAB.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, BLAB.CN has a market cap of 9.7M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while BLAB.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas BLAB.CN's P/E ratio is -1.20. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BLAB.CN's ROE of -4.53%. Regarding short-term risk, DRUG.CN is more volatile compared to BLAB.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs BIOV.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, BIOV.CN has a market cap of 8.7M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while BIOV.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas BIOV.CN's P/E ratio is -1.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BIOV.CN's ROE of +4.49%. Regarding short-term risk, DRUG.CN is less volatile compared to BIOV.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MCUR.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MCUR.CN has a market cap of 7M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MCUR.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MCUR.CN's P/E ratio is -0.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MCUR.CN's ROE of -1.61%. Regarding short-term risk, DRUG.CN is more volatile compared to MCUR.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs COOL.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, COOL.CN has a market cap of 6.8M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while COOL.CN trades at CA$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas COOL.CN's P/E ratio is -1.32. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to COOL.CN's ROE of -2.90%. Regarding short-term risk, DRUG.CN is more volatile compared to COOL.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs APS.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, APS.TO has a market cap of 6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while APS.TO trades at CA$2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas APS.TO's P/E ratio is -0.10. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to APS.TO's ROE of +3.67%. Regarding short-term risk, DRUG.CN is less volatile compared to APS.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs TRYP.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, TRYP.CN has a market cap of 5.8M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while TRYP.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas TRYP.CN's P/E ratio is -1.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TRYP.CN's ROE of +4.03%. Regarding short-term risk, DRUG.CN is more volatile compared to TRYP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs ASEP.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, ASEP.CN has a market cap of 5.6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while ASEP.CN trades at CA$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas ASEP.CN's P/E ratio is -0.83. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ASEP.CN's ROE of -0.40%. Regarding short-term risk, DRUG.CN is more volatile compared to ASEP.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs CMND.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, CMND.CN has a market cap of 5.1M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while CMND.CN trades at CA$1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas CMND.CN's P/E ratio is -0.04. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CMND.CN's ROE of -0.46%. Regarding short-term risk, DRUG.CN is more volatile compared to CMND.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs GTTX.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, GTTX.CN has a market cap of 4.6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while GTTX.CN trades at CA$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas GTTX.CN's P/E ratio is -12.00. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to GTTX.CN's ROE of -0.60%. Regarding short-term risk, DRUG.CN is more volatile compared to GTTX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs AWKN.NE Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, AWKN.NE has a market cap of 3.9M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while AWKN.NE trades at CA$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas AWKN.NE's P/E ratio is -0.36. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to AWKN.NE's ROE of -4.29%. Regarding short-term risk, DRUG.CN is more volatile compared to AWKN.NE. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MYND.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MYND.CN has a market cap of 3.3M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MYND.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MYND.CN's P/E ratio is -3.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MYND.CN's ROE of +0.18%. Regarding short-term risk, DRUG.CN is less volatile compared to MYND.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs IPCI.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, IPCI.TO has a market cap of 2.6M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while IPCI.TO trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas IPCI.TO's P/E ratio is -0.67. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IPCI.TO's ROE of +0.31%. Regarding short-term risk, DRUG.CN is less volatile compared to IPCI.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs APLI.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, APLI.TO has a market cap of 2.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while APLI.TO trades at CA$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas APLI.TO's P/E ratio is -0.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to APLI.TO's ROE of +0.32%. Regarding short-term risk, DRUG.CN is more volatile compared to APLI.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs AGN.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, AGN.CN has a market cap of 2M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while AGN.CN trades at CA$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas AGN.CN's P/E ratio is 2.67. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to AGN.CN's ROE of +0.15%. Regarding short-term risk, DRUG.CN is less volatile compared to AGN.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs MOOD.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, MOOD.CN has a market cap of 1.8M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while MOOD.CN trades at CA$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas MOOD.CN's P/E ratio is -6.67. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to MOOD.CN's ROE of -0.28%. Regarding short-term risk, DRUG.CN is more volatile compared to MOOD.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs ENBI.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, ENBI.CN has a market cap of 1.5M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while ENBI.CN trades at CA$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas ENBI.CN's P/E ratio is -2.75. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ENBI.CN's ROE of -1.33%. Regarding short-term risk, DRUG.CN is more volatile compared to ENBI.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs LEXT.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, LEXT.CN has a market cap of 1.5M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while LEXT.CN trades at CA$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas LEXT.CN's P/E ratio is -0.69. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to LEXT.CN's ROE of -2.39%. Regarding short-term risk, DRUG.CN is less volatile compared to LEXT.CN. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs BRAX.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, BRAX.CN has a market cap of 1.4M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while BRAX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas BRAX.CN's P/E ratio is -0.10. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to BRAX.CN's ROE of -2.49%. Regarding short-term risk, DRUG.CN is more volatile compared to BRAX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs HAVN.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, HAVN.CN has a market cap of 1.2M. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while HAVN.CN trades at CA$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas HAVN.CN's P/E ratio is -0.01. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to HAVN.CN's ROE of +0.00%. Regarding short-term risk, DRUG.CN is more volatile compared to HAVN.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs CHGX.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, CHGX.CN has a market cap of 415.6K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while CHGX.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas CHGX.CN's P/E ratio is -0.50. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CHGX.CN's ROE of +0.23%. Regarding short-term risk, DRUG.CN is more volatile compared to CHGX.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs CURE.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, CURE.CN has a market cap of 408K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while CURE.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas CURE.CN's P/E ratio is 0.17. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to CURE.CN's ROE of -2.58%. Regarding short-term risk, DRUG.CN is more volatile compared to CURE.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs ABRT.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, ABRT.CN has a market cap of 372.1K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while ABRT.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas ABRT.CN's P/E ratio is -0.10. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to ABRT.CN's ROE of +16.27%. Regarding short-term risk, DRUG.CN is more volatile compared to ABRT.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs NSHS.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, NSHS.CN has a market cap of 359.6K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while NSHS.CN trades at CA$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas NSHS.CN's P/E ratio is 0.88. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to NSHS.CN's ROE of +0.09%. Regarding short-term risk, DRUG.CN is more volatile compared to NSHS.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs WBIO.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, WBIO.CN has a market cap of 324.8K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while WBIO.CN trades at CA$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas WBIO.CN's P/E ratio is 0.41. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to WBIO.CN's ROE of +0.01%. Regarding short-term risk, DRUG.CN is more volatile compared to WBIO.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs NIRV.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, NIRV.CN has a market cap of 289.4K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while NIRV.CN trades at CA$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas NIRV.CN's P/E ratio is -0.30. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to NIRV.CN's ROE of +0.00%. Regarding short-term risk, DRUG.CN is more volatile compared to NIRV.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs NOVA.CN Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, NOVA.CN has a market cap of 148.3K. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while NOVA.CN trades at CA$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas NOVA.CN's P/E ratio is -0.05. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to NOVA.CN's ROE of -0.02%. Regarding short-term risk, DRUG.CN is more volatile compared to NOVA.CN. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs IN.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, IN.TO has a market cap of 0. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while IN.TO trades at CA$4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas IN.TO's P/E ratio is -2.77. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to IN.TO's ROE of -162.30%. Regarding short-term risk, DRUG.CN is less volatile compared to IN.TO. This indicates potentially lower risk in terms of short-term price fluctuations for DRUG.CN.
DRUG.CN vs TRIL.TO Comparison
DRUG.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG.CN stands at 249.7M. In comparison, TRIL.TO has a market cap of 0. Regarding current trading prices, DRUG.CN is priced at CA$35.25, while TRIL.TO trades at CA$23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG.CN currently has a P/E ratio of -185.53, whereas TRIL.TO's P/E ratio is -34.06. In terms of profitability, DRUG.CN's ROE is -0.06%, compared to TRIL.TO's ROE of -0.43%. Regarding short-term risk, DRUG.CN is more volatile compared to TRIL.TO. This indicates potentially higher risk in terms of short-term price fluctuations for DRUG.CN.